Pharmacokinetics of orally administered ABT-751 in children with neuroblastoma and other solid tumors
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
To describe the pharmacokinetics of orally administered ABT-751 and its conjugated metabolites in children with neuroblastoma and other solid tumors and to relate pharmacokinetic parameters to toxicity and therapeutic outcomes.
Patients (median age, 11 years) with neuroblastoma (n = 37) or other solid tumors (n = 25) had pharmacokinetic sampling after the first dose of ABT-751 (75–250 mg/m2/day) on a 7-day or 21-day schedule. ABT-751 and its glucuronide and sulfate metabolites were quantified with an HPLC/MS/MS assay. Pharmacokinetic parameters were derived with non-compartmental methods. The relative bioavailability of more water soluble capsule and suspension formulations was assessed.
ABT-751 peaked in plasma at 2 h and declined monoexponentially with a t 1/2 of 5.1 h. The apparent clearance was 33 ml/min/m2 and was age-independent. The AUC0–∞ increased in proportion to the dose, and at 200 mg/m2 the median AUC0–∞ was 91 mcg h/ml and the C ave was 3.9 mcg/ml. Inter-and intra-patient variability was low. The metabolites were detected in plasma 30 min post-dose and peaked 3–5 h after the dose. The glucuronide:sulfate molar AUC0–∞ ratio was 0.57. Less than 1% of the dose was excreted in urine as parent drug; 13% of the dose was excreted as sulfate metabolite and 10% as glucuronide metabolite. The relative bioavailability of the water soluble capsule and suspension formulations was 105 and 93%, respectively. AUC0–∞ was higher in patients experiencing dose-limiting toxicity.
Oral ABT-751 pharmacokinetics was dose-proportional and age-independent with minimal intra- and inter-patient variability in children.
- Iwamoto Y, Nishio K, Fukumoto H, Yoshimatsu K, Yamakido M, Saijo N (1998) Preferential binding of E7010 to murine beta 3-tubulin and decreased beta 3-tubulin in E7010-resistant cell lines. Jpn J Cancer Res 89(9):954–962
- Yoshimatsu K, Yamaguchi A, Yoshino H, Koyanagi N, Kitoh K (1997) Mechanism of action of E7010, an orally active sulfonamide antitumor agent: inhibition of mitosis by binding to the colchicine site of tubulin. Cancer Res 57(15):3208–3213
- Fox E, Maris JM, Widemann BC et al (2008) A phase I study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 21 days every 28 days in pediatric patients with solid tumors. Clin Cancer Res 14(4):1111–1115 CrossRef
- Fox E, Maris JM, Widemann BC et al (2006) A phase 1 study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 7 days every 21 days in pediatric patients with solid tumors. Clin Cancer Res 12(16):4882–4887 CrossRef
- Hande KR, Hagey A, Berlin J et al (2006) The pharmacokinetics and safety of ABT-751, a novel, orally bioavailable sulfonamide antimitotic agent: results of a phase 1 study. Clin Cancer Res 12(9):2834–2840 CrossRef
- Yee KW, Hagey A, Verstovsek S et al (2005) Phase 1 study of ABT-751, a novel microtubule inhibitor, in patients with refractory hematologic malignancies. Clin Cancer Res 11(18):6615–6624 CrossRef
- Meany H, Fox E, Hagey AE, Balis FM (2006) In vitro cytotoxicity of ABT-751, a novel tubulin inhibitor, in pediatric solid tumor cell lines. Proc Am Assoc Cancer Res 47:1021 (Abstr #4351)
- Morton CL, Favours EG, Mercer KS et al (2007) Evaluation of ABT-751 against childhood cancer models in vivo. Invest New Drugs 25(4):285–295 CrossRef
- Fox E, Adamson PC, Hagey A, et al (2005) Phase I trial of oral ABT-751 in pediatric patients: preliminary evidence of activity in neuroblastoma (NBL). J Clin Oncol. ASCO Ann Meeting Proc 2005; 23(June 1 Suppl) (16S, Part 1 of 2: Abstr # 8527)
- Rudek MA, Zhao M, He P, Messersmith WA, Baker SD (2006) Validation and implementation of a liquid chromatography/tandem mass spectrometry assay to quantitate ABT-751, ABT-751 glucuronide, and ABT-751 sulfate in human plasma for clinical pharmacology studies. J Pharm Biomed Anal 42(2):253–260 CrossRef
- Pharmacokinetics of orally administered ABT-751 in children with neuroblastoma and other solid tumors
Cancer Chemotherapy and Pharmacology
Volume 66, Issue 4 , pp 737-743
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- Tubulin binding agent
- Industry Sectors
- Author Affiliations
- 1. Pediatric Oncology Branch, National Cancer Institute, 10 Center Drive, Bldg. 10/Rm. 1-5750, Bethesda, MD, 20892-1101, USA
- 2. Center for Childhood Cancer Research at The Children’s Hospital of Philadelphia and University of Pennsylvania School of Medicine, Philadelphia, PA, USA
- 3. University of Chicago, Chicago, IL, USA
- 4. Abbott Laboratories, Abbott Park, IL, USA